Premium
Differential expression analysis of mi RNA in peripheral blood mononuclear cells of patients with non‐segmental vitiligo
Author(s) -
Wang Yi,
Wang Keyu,
Liang Jianhua,
Yang Hong,
Dang Ningning,
Yang Xi,
Kong Yi
Publication year - 2015
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12725
Subject(s) - vitiligo , peripheral blood mononuclear cell , rna , microrna , immune system , immunology , real time polymerase chain reaction , gene expression , biology , gene , medicine , genetics , in vitro
Vitiligo is a common depigmentary skin disease that may follow a pattern of multifactorial inheritance. The essential factors of its immunopathogenesis is thought to be the selective destruction of melanocytes. As a new class of microregulators of gene expression, mi RNA have been reported to play vital roles in autoimmune diseases, metabolic diseases and cancer. This study sought to characterize the different mi RNA expression pattern in the peripheral blood mononuclear cells ( PBMC ) of patients with non‐segmental vitiligo ( NSV ) and healthy individuals and to examine their direct responses to thymosin α1 (Tα1) treatment. The mi RNA expression profile in the PBMC of patients with NSV was analyzed using Exiqon's miRCURY LNA microRNA Array. The differentially expressed mi RNA were validated by real‐time quantitative polymerase chain reaction. We found that the expression levels of miR‐224‐3p and miR‐4712‐3p were upregulated, and miR‐3940‐5p was downregulated in the PBMC . The common clinical immune modulator Tα1 changed the mi RNA expression profile. Our analysis showed that differentially expressed mi RNA were associated with the mechanism of immune imbalance of vitiligo and that Tα1 could play an important role in changing the expression of these mi RNA in the PBMC of patients with NSV . This study provided further evidence that mi RNA may serve as novel drug targets for vitiligo therapeutic evaluation.